Stockscreener 앱 받기
83.18
0.10%
-0.08
시간 외 거래:
83.28
0.10
+0.12%
전일 마감가:
$83.26
열려 있는:
$84.19
하루 거래량:
11.75M
Relative Volume:
0.70
시가총액:
$198.14B
수익:
$63.92B
순이익/손실:
$17.43B
주가수익비율:
12.11
EPS:
6.87
순현금흐름:
$18.10B
1주 성능:
+0.53%
1개월 성능:
-3.95%
6개월 성능:
-18.35%
1년 성능:
-35.15%
1일 변동 폭
$82.95
$84.71
1주일 범위
$82.40
$85.83
52주 변동 폭
$75.93
$134.63
머크앤드컴퍼니 Stock (MRK) Company Profile
명칭
Merck Co Inc
전화
908-740-4000
주소
2000 GALLOPING HILL ROAD, KENILWORTH, NJ
MRK을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
MRK
Merck Co Inc
|
83.18 | 198.14B | 63.92B | 17.43B | 18.10B | 6.87 |
|
LLY
Lilly Eli Co
|
823.62 | 713.24B | 45.04B | 10.59B | 414.30M | 11.71 |
|
JNJ
Johnson Johnson
|
156.12 | 370.90B | 89.33B | 21.81B | 18.57B | 8.99 |
|
ABBV
Abbvie Inc
|
198.47 | 329.14B | 57.37B | 4.20B | 17.83B | 2.35 |
|
NVO
Novo Nordisk Adr
|
69.23 | 275.58B | 42.09B | 14.65B | 10.11B | 3.2833 |
|
NVS
Novartis Ag Adr
|
114.29 | 221.49B | 53.22B | 12.86B | 14.85B | 6.39 |
머크앤드컴퍼니 Stock (MRK) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-04-22 | 개시 | Cantor Fitzgerald | Neutral |
| 2025-02-18 | 다운그레이드 | Deutsche Bank | Buy → Hold |
| 2025-02-10 | 다운그레이드 | TD Cowen | Buy → Hold |
| 2025-01-08 | 다운그레이드 | Truist | Buy → Hold |
| 2024-12-20 | 다운그레이드 | BMO Capital Markets | Outperform → Market Perform |
| 2024-12-10 | 재개 | BofA Securities | Buy |
| 2024-12-04 | 업그레이드 | HSBC Securities | Hold → Buy |
| 2024-11-15 | 개시 | Wolfe Research | Peer Perform |
| 2024-11-11 | 다운그레이드 | Daiwa Securities | Buy → Neutral |
| 2024-10-17 | 개시 | Bernstein | Mkt Perform |
| 2024-03-11 | 다운그레이드 | Societe Generale | Hold → Sell |
| 2024-01-04 | 업그레이드 | TD Cowen | Market Perform → Outperform |
| 2023-11-09 | 개시 | Deutsche Bank | Buy |
| 2023-10-27 | 업그레이드 | BMO Capital Markets | Market Perform → Outperform |
| 2023-10-20 | 업그레이드 | UBS | Neutral → Buy |
| 2023-07-14 | 개시 | HSBC Securities | Hold |
| 2023-04-13 | 업그레이드 | Citigroup | Neutral → Buy |
| 2023-03-28 | 다운그레이드 | Societe Generale | Buy → Hold |
| 2023-03-13 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2023-03-06 | 개시 | Jefferies | Buy |
| 2023-02-22 | 업그레이드 | Wolfe Research | Peer Perform → Outperform |
| 2023-01-04 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2022-11-18 | 개시 | Credit Suisse | Outperform |
| 2022-10-10 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2022-09-14 | 업그레이드 | Berenberg | Hold → Buy |
| 2022-07-06 | 업그레이드 | Daiwa Securities | Neutral → Buy |
| 2022-06-06 | 재개 | SVB Leerink | Outperform |
| 2022-04-06 | 재개 | Morgan Stanley | Equal-Weight |
| 2021-12-17 | 개시 | Goldman | Buy |
| 2021-12-16 | 개시 | Daiwa Securities | Neutral |
| 2021-12-13 | 다운그레이드 | UBS | Buy → Neutral |
| 2021-12-09 | 개시 | Wells Fargo | Overweight |
| 2021-12-07 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2021-11-29 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2021-11-19 | 개시 | BMO Capital Markets | Market Perform |
| 2021-11-01 | 업그레이드 | Argus | Hold → Buy |
| 2021-09-07 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2021-07-27 | 재개 | Truist | Buy |
| 2021-05-20 | 다운그레이드 | Argus | Buy → Hold |
| 2021-04-07 | 재개 | RBC Capital Mkts | Sector Perform |
| 2020-11-10 | 재개 | Bernstein | Outperform |
| 2020-09-29 | 개시 | Berenberg | Hold |
| 2020-08-03 | 업그레이드 | Goldman | Neutral → Buy |
| 2020-06-12 | 다운그레이드 | Wolfe Research | Outperform → Peer Perform |
| 2020-02-27 | 개시 | Barclays | Overweight |
| 2020-01-07 | 개시 | RBC Capital Mkts | Sector Perform |
| 2019-10-17 | 재개 | BofA/Merrill | Neutral |
| 2019-08-16 | 개시 | SVB Leerink | Outperform |
| 2019-07-03 | 개시 | Mizuho | Buy |
| 2019-05-28 | 개시 | Goldman | Neutral |
| 2019-05-13 | 업그레이드 | Atlantic Equities | Neutral → Overweight |
| 2018-10-16 | 재확인 | Citigroup | Buy |
| 2018-10-09 | 재개 | Guggenheim | Buy |
| 2018-04-23 | 업그레이드 | Goldman | Neutral → Buy |
| 2018-04-17 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2018-04-05 | 업그레이드 | Barclays | Equal Weight → Overweight |
| 2018-03-12 | 업그레이드 | Leerink Partners | Mkt Perform → Outperform |
| 2018-02-14 | 재확인 | Leerink Partners | Mkt Perform |
| 2018-02-07 | 재확인 | Morgan Stanley | Equal-Weight |
| 2018-01-16 | 업그레이드 | SunTrust | Hold → Buy |
모두보기
머크앤드컴퍼니 주식(MRK)의 최신 뉴스
Merck & Co., Inc. SEC 10-Q Report - TradingView
Merck & Co. CMO Barr On Breaking Into Immunology And Ophthalmology - insights.citeline.com
Liver Cancer Treatment Market is expected to generate a revenue of USD 8.88 Billion by 2031, Globally, at 13.45% CAGR: Verified Market Research® - GlobeNewswire Inc.
Merck & Co., Inc. (MRK): Jim Cramer Agrees – “Merck’s A Good Company” - Insider Monkey
Jim Cramer Says He Likes Bristol-Myers Squibb (BMY) More Than Merck Due to Schizophrenia Drug - Yahoo Finance
Arvinas, Entrada cut staff; Merck builds US hub for Keytruda - BioPharma Dive
June 13th Options Now Available For Merck (MRK) - Nasdaq
Investors Heavily Search Merck & Co., Inc. (MRK): Here is What You Need to Know - Yahoo Finance
AmacaThera and Merck Animal Health Announce Collaboration in Animal Health - PR Newswire
Pharmaceutical company Merck to invest $1 billion in Delaware plant - The American Bazaar
Is Merck & Co. Inc. (MRK) the Best Dow Stock for the Next 12 Months? - Yahoo Finance
In Brief: Merck To Invest $1bn In New US Biologics Production - insights.citeline.com
Merck & Co courts Washington with Delaware build statement - The Pharma Letter
Merck Shareholder Drops Suit Against Execs Over Gardasil Demand - Bloomberg Law News
Merck & Co., Inc. (MRK): Among Billionaire Cliff Asness’ Stock Picks with Huge Upside Potential - Insider Monkey
Guggenheim Adjusts Merck & Co.'s Price Target to $108 From $115 - marketscreener.com
Guggenheim cuts Merck stock target to $108, keeps Buy rating By Investing.com - Investing.com India
Merck (MRK) Price Target Reduced by Guggenheim Analyst | MRK Sto - GuruFocus
Merck & Co. (MRK) Looks to New Cholesterol Drug as Keytruda Expiration Looms - TipRanks
Analysis of Cancer Immunotherapy Technologies and Global Markets to 2029 - GlobeNewswire Inc.
Merck plans to move manufacturing of its biggest drug, Keytruda, to a new US factory and lab in Delaware - The Daily Gazette
Merck breaks ground at Chestnut Run - WDEL.com
How To Put $100 In Your Retirement Fund Each Month With Merck Stock - Benzinga
Merck to invest $1 billion in new Delaware plant to boost US manufacturing - Reuters
Merck plans to bring Keytruda production to the US with $1B biologics factory - Endpoints News
Is Merck & Co., Inc. (MRK) the Worst-Performing Blue Chip Stock So Far in 2025? - Insider Monkey
Merck to build $1B biologics center in Wilmington - The Business Journals
Merck Begins Construction of $1 Billion Biologics Facility in Delaware - marketscreener.com
Merck to invest $1 billion in U.S. drug manufacturing plant - CBS News
Merck Breaks Ground on New $1 Billion Biologics Center of Excellence in Wilmington, Delaware | MRK Stock News - GuruFocus
Merck (MRK) to Invest $1 Billion in Delaware Manufacturing Plant - GuruFocus
Merck Breaks Ground On New $1 Billion Biologics Center Of Excellence In Wilmington, Delaware - marketscreener.com
Merck (MRK) Commences Construction on Advanced Biologics Facilit - GuruFocus
Merck to build $1B Delaware plant to ensure domestic supply of Keytruda (MRK:NYSE) - Seeking Alpha
Stock Watch: Sanofi, Merck Open Windows Into Geopolitical Risks - insights.citeline.com
Merck to invest $1 billion in new US site - breakingthenews.net
Merck to invest $1 billion in new Delaware plant to boost US manufacturing, WSJ reports - marketscreener.com
Merck To Spend $1 Billion On New Factory To Make U.S. Supplies Of Cancer Drug Keytruda- WSJ - marketscreener.com
Exclusive | Merck to Spend $1 Billion on New Factory to Make U.S. Supplies of Blockbuster Drug - WSJ
Merck Set To Add Perioperative Head-And-Neck Cancer To Keytruda Label - insights.citeline.com
Merck & Co. CMO Eliav Barr Assures On Pipeline As Keytruda LOE Looms Large - insights.citeline.com
Merck Germany Buys US Cancer Drugmaker SpringWorks Therapeutics For Around $4 Billion - Benzinga
Jim Cramer Says Merck & Co (MRK) Has ‘Turned Into a Complete Nightmare’ - Insider Monkey
Is Merck & Co., Inc. (MRK) the Most Profitable Blue Chip Stock to Buy Now? - Insider Monkey
HSBC Adjusts Merck & Co Price Target to $100 From $115, Maintains Buy Rating - marketscreener.com
Earnings Update: Merck & Co., Inc. (NYSE:MRK) Just Reported Its First-Quarter Results And Analysts Are Updating Their Forecasts - simplywall.st
80% of the EVX-01 vaccine targets trigger a tumor-reactive immune response - GlobeNewswire Inc.
Germany’s Merck Set to Buy SpringWorks in $3.9 Billion Deal - WSJ
Merck KGaA strikes $3.9bn deal for SpringWorks - Pharmaceutical Technology
Merck: positive results in head & neck cancer - marketscreener.com
Merck's Keytruda Improves Head and Neck Cancer Survival by 34% in Study - marketscreener.com
머크앤드컴퍼니 (MRK) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.66%
0.90%
자본화:
|
볼륨(24시간):